June 24, 2026 marks one year since the U.S. Food and Drug Administration issued the import alert that blocked 58 Olympus device models from entering the United States. A year later, the alert is still in place. The FDA has not announced verification of Olympus's claimed corrective work. Three new 2026 recalls have widened the compliance picture rather than narrowed it. Individual lawsuits continue to be filed in state and federal courts. And there is still no MDL.
October 2026 Update
The sections under this one are the mid-June 2026 record. What follows is the status checked on October 12, 2026. It is about recalled Olympus endoscopes and the machines that clean them, and about an Olympus endoscope infection lawsuit as an individual claim. It is not a statement that any reader has a claim.
What the FDA record still shows
The FDA recall database still lists Recall Z-1613-2026 as Open and Classified. That record is the Olympus OER-Pro reprocessor, model N3058140, 3,354 units, initiated February 12, 2026, because the MAJ-1443 and MAJ-1444 valves are no longer reprocessing compatible with the OER-Pro and OER-Elite. An open status means not all products have been corrected or removed. A separate OER-Pro safety alert, Z-0873-2026, initiated October 31, 2025, is also still open. The details are on the OER-Pro recall page.
The FDA’s June 24, 2025 letter is still the notice posted for the Aizu import alerts. It says specified bronchoscopes, ureterorenoscopes, laparoscopes, and automated endoscope reprocessors will be refused entry. It also says that if a facility is currently using a listed device, it may continue if it is not experiencing problems with that device, and it tells users to follow the labeling and reprocessing instructions. The letter does not say the alerts have been lifted. Olympus’s June 27, 2025 acknowledgment described the same import block and said the action prevents import of the specified devices into the United States until further notice. That notice does not say the alerts were later withdrawn.
Class action, MDL, or an individual claim
Searches for an “Olympus endoscope class action” and an “Olympus scope contamination lawsuit” are not the same question. A class action, under Federal Rule of Civil Procedure 23, is one case that a court must certify before it can bind a group. An MDL, under 28 U.S.C. § 1407, keeps each lawsuit separate and sends federal cases that share common facts to one judge for pretrial work. An individual claim is filed and decided on that person’s procedure, culture, and records.
The Judicial Panel on Multidistrict Litigation’s pending MDL report dated September 1, 2026 does not list an Olympus, duodenoscope, or endoscope-infection docket. That report is a list of transferred MDLs. It is not a list of class actions, and it is not a promise that no complaint of any kind exists in any court. What it does support is this: no consolidated Olympus endoscope MDL had been transferred and listed as of that report. The JPML pending-reports archive, reviewed October 12, 2026, lists September 2026 as the newest report and does not list an October 2026 report. There is no national settlement described in the September 1 report, and this page does not describe one.
For a patient, the practical point is that an Olympus endoscope infection lawsuit of this kind is being handled as an individual claim, not as a class someone joins by signing a form. A longer explanation of the three paths is on class action versus MDL versus an individual lawsuit. A review of your dates and records is free. A review does not mean you qualify, and nothing here predicts a result.
Why the Anniversary Matters
Import alerts are not permanent by design. They are administrative tools the FDA uses to block products from entering the United States until the underlying quality system violations are resolved. Most import alerts of this scale — covering 58 device models from a single facility — are resolved within months once a manufacturer demonstrates corrective action.
The Aizu, Japan import alert has now been in place for a full year. Olympus disclosed in its most recent investor materials that it had completed roughly 96% of the corrective actions tied to the FDA's quality system findings. The FDA has not independently verified that figure, has not lifted the alert, and has not publicly announced a timetable.
For patients and families with potential cases, the persistence of the alert matters in two ways. First, the alert is a formal regulatory finding that documents quality system violations — the kind of record that becomes evidence in product liability cases. Second, the fact that the FDA has not lifted it, despite Olympus's claimed near-completion, suggests the agency is not yet satisfied with the corrective work.
The 2026 Recall Pattern in Retrospect
Looking at 2026 in retrospect, the import alert is no longer an isolated event. Three additional Olympus recalls have entered the FDA database in the past six months:
- January 16, 2026 — High Flow Insufflation Units. A Class I recall covering the UHI, UHI-2, and UHI-3 insufflation units. The FDA ultimately tied this recall to 10 injuries and one death. Because no software correction was available, Olympus removed the products from the market entirely.
- January 22, 2026 — Endoscope needle recall expansion. An expansion of an earlier recall covering disposable endoscope needles produced at the same Aizu facility.
- February 12, 2026 (posted March 20, 2026) — OER-Pro automated endoscope reprocessor recall. 3,354 units of the cleaning device hospitals use to reprocess Olympus duodenoscopes between patients, recalled due to MAJ-1443 and MAJ-1444 component incompatibilities. We covered this in our June 2026 litigation status update.
Three recalls in six months, across three different product categories (insufflation, disposable accessories, reprocessing equipment), is not the pattern of a manufacturer whose compliance work is winding down. It is the pattern of a manufacturer whose quality system problems continue to surface.
U.S. Litigation: Still Individual, Still No MDL
The structural picture in U.S. federal court is unchanged from our April, May, and early June updates. The Judicial Panel on Multidistrict Litigation has not consolidated Olympus duodenoscope cases. The spring 2026 JPML hearing sessions did not take up the question. The summer JPML session is the next natural opportunity, but no public docket entry suggests a centralization motion has been filed.
Plaintiffs continue to file individual product liability actions in state and federal courts across the country. Each case proceeds at the pace of its own court. There is no consolidated discovery, no MDL bellwether schedule, and no national settlement framework on the table.
What that means for prospective plaintiffs is the same thing we've said every month this year: your filing window is set by your state's statute of limitations, and that clock does not pause while everyone waits to see whether an MDL forms.
What to Do as Summer 2026 Approaches
Summer is a particularly relevant time of year to revisit a possible scope infection case. A few specific reasons:
- Spring colonoscopy season is winding down. Patients who had procedures in March, April, and May 2026 are now in the post-procedure window where infection symptoms typically present. Our scope infection symptom timeline guide walks through what to watch for.
- Statute of limitations dates are approaching for many earlier-injury patients. Patients hurt by Olympus scopes in 2024 may be running up against two- or three-year state filing deadlines this summer.
- The import alert may yet lift. If the FDA verifies Olympus's corrective work and lifts the alert in the second half of 2026, the regulatory pressure on the company changes, and so do settlement dynamics. Cases filed before any such shift are positioned to benefit from the current record.
- Hospital records have not yet aged out. Most hospitals retain procedure-level records and reprocessing logs for the time period of the 2024-2025 cases. Records requests filed now still produce complete files.
What to Watch the Rest of June
- The June 24 anniversary. Watch for any FDA announcement on or near that date regarding the Aizu facility status.
- Olympus quarterly earnings disclosures. The company's June-period investor disclosures typically include updates on regulatory progress and contingent liabilities related to the litigation.
- Any new field safety notices. The pattern of 2026 recalls suggests the next one is more likely than not within a few months.
- The Quebec class action. Documents produced in the April 2026 Siskinds LLP Quebec filing may eventually surface in U.S. discovery channels.
If You Were Affected
We represent patients nationwide, regardless of where the procedure happened. A free case review takes about 15 minutes by phone. We evaluate the medical timeline, the device involved, and your state's filing deadlines before you decide whether to move forward.
- See if your situation fits the case profile with our 3-part qualification test.
- Learn how to identify which scope was used in your procedure: Did Your Hospital Use Olympus Scopes?
- Review the superbug infection symptoms guide for warning signs to watch for.
- Read the regulatory backdrop: What the June 2025 FDA Import Alert Means for You.
- Read the prior cadence post: June 4, 2026 — When the Cleaning Equipment Itself Gets Recalled.
Free case review. No Fees Unless We Recover Money for You.
Sources
- U.S. Food & Drug Administration — "Import Alerts for Certain Olympus Medical Devices Manufactured in Japan: Letter to Health Care Providers" (June 24, 2025). fda.gov
- Olympus Corporation — Investor disclosures on quality-commitment progress and import-alert status. olympus-global.com/ir
- U.S. Food & Drug Administration — "Insufflation Unit Recall: Olympus Removes High Flow Insufflation Units" (January 2026, Class I). fda.gov
- FierceBiotech — "FDA links Olympus laparoscopic insufflation hardware recall to 10 injuries, one death." fiercebiotech.com
- American Hospital Association — "Olympus expands recall of endoscope needles" (January 22, 2026). aha.org
- U.S. FDA Medical Device Recalls Database — Olympus OER-Pro automated endoscope reprocessor (initiated February 12, 2026; posted March 20, 2026; 3,354 units). accessdata.fda.gov
- Judicial Panel on Multidistrict Litigation — MDL Statistics Report, Distribution of Pending MDL Dockets by Actions Pending, report date September 1, 2026 (no Olympus, duodenoscope, or endoscope-infection docket in the report text). jpml.uscourts.gov
- Judicial Panel on Multidistrict Litigation — Pending MDL Reports Archive (reviewed October 12, 2026; newest listed report is September 2026; no October 2026 report listed). jpml.uscourts.gov
- U.S. Food & Drug Administration — Class 2 Device Recall Z-1613-2026, Olympus Endoscope Reprocessor OER-Pro, status Open and Classified as reviewed October 12, 2026. accessdata.fda.gov
- U.S. Food & Drug Administration — Class 2 Device Recall Z-0873-2026, Olympus OER-Pro safety alert initiated October 31, 2025, status Open and Classified. accessdata.fda.gov
- Olympus Corporation — “Olympus Acknowledges FDA Import Alerts for Certain Devices Manufactured at Aizu Facility, Japan” (June 27, 2025). olympus-global.com
- U.S. FDA MAUDE Adverse Event Database — Olympus duodenoscope reports. accessdata.fda.gov
Think You May Have a Case?
The 3-part qualification test takes 2 minutes. If it fits your situation, a free case review is the next step. No Fees Unless We Recover Money for You.